Date of submission: July 31, 2026

To,	To,
The Secretary Listing Department **BSE Limited** Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 **Scrip Code – 539551 (EQ), 975516 & 976418**	The Secretary Listing Department **National Stock Exchange of India Limited** Exchange Plaza, Bandra Kurla Complex Mumbai – 400 051 **Scrip Code- NH**

Dear Sir/Madam,

Sub: Outcome of the Board Meeting held on July 31, 2026

Pursuant to Regulation 30 read with Regulations 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015 ("SEBI Listing Regulations"), this is to inform you that the Board of Directors of the Company at its meeting held **today, i.e. July 31, 2026** (Friday) *inter alia*, has approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026 together with the Limited Review Report reviewed by the Audit Committee and approved by the Board of Directors.

A copy of the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026 together with Limited Review Report is enclosed as **Annexure** for your information.

The meeting of the Board of Directors commenced at 03:30 P.M. IST and ended at 06:00 P.M. IST.

This is for your information and records.

Thanking you

Yours faithfully
For **Narayana Hrudayalaya Limited**

SESHIAH SRIDHAR Digitally signed by SESHIAH SRIDHAR Date: 2026.07.31 19:14:37 +05'30'

Sridhar S.
Group Company Secretary, Legal & Compliance Officer

Encl.: as above

Deloitte
Haskins & Sells LLP

Chartered Accountants
Prestige Trade Tower, Level 19
46, Palace Road, High Grounds
Bengaluru – 560 001
Karnataka, India

Tel: +91 80 6188 6000
Fax: +91 80 6188 6011

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
NARAYANA HRUDAYALAYA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **NARAYANA HRUDAYALAYA LIMITED** ("the Company"), for the quarter ended June 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

SATHYA PRAMOD KOUSHIK
Digitally signed by SATHYA PRAMOD KOUSHIK
Date: 2026.07.31 18:15:58 +05'30'

Sathya P. Koushik
Partner
(Membership No. 206920)
UDIN: 26206920AEJSKX6881

Place: Bengaluru
Date: July 31, 2026
SPK/SG/TG/AB/2026

Narayana Hrudayalaya Limited

Registered office : No. 258/A, Bommasandra Industrial Area, Anekal Taluk, Bengaluru 560099, Karnataka, India
Corporate office : 2nd Floor, No. 261/A, Bommasandra Industrial Area, Hosur Road, Bengaluru 560099, Karnataka, India
CIN : L85110KA2000PLC027497, Website : www.narayanahealth.org, Email: investorrelations@narayanahealth.org

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026

(₹ in million except per share data)

Sl. No.	Particulars	Quarter ended			Year Ended
		30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
		(Unaudited)	(Unaudited) Refer Note 5	(Unaudited)	(Audited)
1.	Income				
	(a) Revenue from operations	10,971.02	10,440.50	9,431.41	39,751.41
	(b) Other income (refer note 4)	304.13	1,270.59	164.36	1,764.34
	Total income	**11,275.15**	**11,711.09**	**9,595.77**	**41,515.75**
2.	Expenses				
	(a) Purchases of medical consumables, drugs, surgical instruments and other consumables	2,599.81	2,389.86	2,211.31	9,134.03
	(b) Changes in inventories of medical consumables, drugs, surgical instruments and other consumables - (Increase) / Decrease	(29.77)	(10.45)	28.29	30.53
	(c) Employee benefits expense	1,912.19	1,747.20	1,761.55	7,053.80
	(d) Professional fees to doctors	2,201.89	2,239.38	1,935.62	8,189.31
	(e) Other expenses	1,895.68	1,808.36	1,704.46	6,949.26
	Expenses before depreciation and amortisation, finance costs and exceptional items	**8,579.80**	**8,174.35**	**7,641.23**	**31,356.93**
3.	**Earnings before depreciation and amortisation, finance costs and exceptional items (1-2) (EBITDA)**	**2,695.35**	**3,536.74**	**1,954.54**	**10,158.82**
4.	Finance costs	336.66	387.82	306.23	1,271.16
5.	Depreciation and amortisation expense	481.48	507.10	475.58	1,914.78
6.	**Total expenses (2+4+5)**	**9,397.94**	**9,069.27**	**8,423.04**	**34,542.87**
7.	**Profit before tax and exceptional items (1-6)**	**1,877.21**	**2,641.82**	**1,172.73**	**6,972.88**
8.	Exceptional item (refer note 8)	-	-	-	(452.76)
9.	**Profit before tax (7+8)**	**1,877.21**	**2,641.82**	**1,172.73**	**6,520.12**
10.	Tax expense				
	(a) Current tax				
	-Current year	481.11	690.41	286.61	1,564.92
	(b) Deferred tax charge/(credit)	17.55	(69.84)	12.41	(75.93)
	Total tax expense	**498.66**	**620.57**	**299.02**	**1,488.99**
11.	**Net Profit for the period/ year (9-10)**	**1,378.55**	**2,021.25**	**873.71**	**5,031.13**
12.	**Other comprehensive income**				
	Items that will not be reclassified subsequently to profit or loss				
	(i) Re-measurement gains/(losses) on defined benefit plans	(46.38)	20.84	(7.64)	9.45
	(ii) Income tax effect	11.67	(5.25)	1.92	(2.38)
	Items that will be reclassified subsequently to profit or loss				
	(i) Effective portion of gains/ (losses) in cash flow hedge	-	-	1.73	(6.90)
	(ii) Income tax effect	-	-	(0.44)	-
	Other comprehensive income/(loss), net of taxes	**(34.71)**	**15.59**	**(4.43)**	**0.17**
13.	**Total comprehensive income for the period/year (11+12)**	**1,343.84**	**2,036.84**	**869.28**	**5,031.30**
14.	Paid-up equity share capital (Face value of ₹ 10 each)	2,043.61	2,043.61	2,043.61	2,043.61
15.	Reserves (Other Equity)	-	-	-	23,930.71
16.	Earnings / (loss) per share (of ₹ 10 each) :	not annualised	not annualised	not annualised	annualised
	(a) Basic	6.79	9.95	4.30	24.77
	(b) Diluted	6.79	9.95	4.30	24.77
	See accompanying notes to the standalone financial results				

HASKINS & SELLS LLP DELOITTE CHARTERED ACCOUNTANTS BENGALURU

Narayana Hrudayalaya Limited

Narayana Hrudayalaya Limited
Registered office : No. 258/A, Bommasandra Industrial Area, Anekal Taluk, Bengaluru 560099, Karnataka, India
Corporate office : 2nd Floor, No. 261/A, Bommasandra Industrial Area, Hosur Road, Bengaluru 560099, Karnataka, India
CIN : L85110KA2000PLC027497, Website : www.narayanahealth.org, Email: investorrelations@narayanahealth.org

Notes :

1 The Statement of unaudited standalone financial results ('the Statement') for the quarter ended 30 June 2026 of Narayana Hrudayalaya Limited ('the Company') has been reviewed by the Audit, Risk and Compliance Committee and approved by the Board of Directors of the Company at their respective meetings held on 31 July 2026. The statutory auditors have expressed an unmodified review conclusion on the unaudited standalone financial results for the quarter ended 30 June 2026.

The aforesaid results along with limited review report of the statutory auditors on the unaudited standalone financial results for the quarter ended 30 June 2026, is being filed with the National Stock Exchange of India limited ("NSE") and BSE Limited ('BSE') and is also available on the Company's website.

2 The Statement has been prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standard ("Ind AS") 34 'Interim financial reporting' prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

3 The Company's operating segment is 'Medical and Healthcare Related Services'. Since the Company has a single operating segment, disclosure pertaining to segments as per Regulation 33(1)(e) read with clause (L) of Part A of Schedule IV of the SEBI Regulations is not applicable.

4 Other income for the quarter and year ended 31 March 2026 includes dividend income from Health City Cayman Islands limited (HCCI), wholly owned subsidiary amounting to ₹ 943.52 million.

5 The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures in respect of the financial year ended 31 March 2026 and the published year to date figures for the nine months ended 31 December 2025, which were subjected to limited review by the statutory auditors.

6 The Board of Directors of the Company at its meeting held on 29 November 2024 approved the Scheme of Arrangement for the Merger of Meridian Medical Research & Hospital Ltd. (MMRHL), the subsidiary ("Transferor Company") with the Company ("Transferee Company") and their respective Shareholders and Creditors under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ("the Scheme") with 1 April 2024 as the appointed date and have recommended 1 (One) equity share of the Company to the shareholders of MMRHL (other than the Company) for every 2 (Two) fully paid-up equity shares of MMRHL.

The Stock Exchanges, BSE and NSE, after reviewing the Scheme filed with them by the Company on 20 December 2024 under Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, had issued "No Observation Letter" on 23 June 2025 and 24 June 2025, respectively under the said Regulations and the Scheme was filed with the Hon'ble National Company Law Tribunal, Bengaluru Bench (NCLT) on 27 September 2025.

Pursuant to the Order dated 2 December 2025 issued by the Hon'ble NCLT, the meetings of the Creditors and the Shareholders of the Transferor Company and the Transferee Company were held on 19 January 2026 who have passed the Scheme with more than requisite majority. Post approval by the Creditors and the Shareholders, a Petition along with the voting results has been filed with the Hon'ble NCLT on 23 January 2026. Notices were dispatched to all the Regulatory Authorities for seeking their 'No Objection' with respect to the merger of MMRHL with the Company. Upon receipt of No-Objection letters from the Regulatory Authorities and basis the hearings, the Final Order by the Hon'ble NCLT is expected to be received in due course. Further, there is no impact on results for the quarter ended 30 June 2026.

7 The Board of Directors of the Company at the meeting held on 12 December 2025 had approved the Scheme of Arrangement between NH Integrated Care Private Limited (NHIC) (Wholly Owned Subsidiary) ["Demerged Company "], Narayana Hrudayalaya Limited ("Resulting Company") and their respective shareholders and creditors to demerge the clinical services as defined in the scheme of NHIC ('the Demerged Undertaking') into the Resulting Company, while continuing the Narayana Aarogyam Vertical within NHIC, on a going concern basis under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ('the Scheme') with 1 April 2025 as the Appointed Date.

The Scheme was filed with the NCLT, Bengaluru Bench on 17 December 2025. Pursuant to the Order dated 13 February 2026 issued by the Hon'ble NCLT, the meetings of the Creditors and the Shareholders of the Demerged Company and the Resulting Company were held on 2 April 2026 who have passed the Scheme with more than requisite majority. Post approval by the Creditors and the Shareholders, a Petition along with the voting results has been filed with the Hon'ble NCLT on 8 April 2026. There will be no issuance of shares as consideration, in view of the Demerged Company being a wholly-owned subsidiary of the Resulting Company. Notices were dispatched to all the Regulatory Authorities for seeking their 'No Objection' with respect to above-mentioned scheme of arrangement. Upon receipt of No-Objection letters from the Regulatory Authorities and basis the hearings, the Final Order by the Hon'ble NCLT is expected to be received in due course. Further, there is no impact on results for the quarter ended 30 June 2026.

8 On 21 November 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "Labour Codes"). These Labour Codes consolidate twenty-nine existing labour laws into a unified framework governing employee benefits during and post-employment. The Labour Codes amongst other things introduced changes including a uniform definition of wages and enhanced benefit to leave.

The Company had assessed the financial implications of these changes which had resulted in increase in gratuity liability and leave liability arising out of past service cost by ₹452.76 million for the year ended 31 March 2026. As the impact arises from the enactment of new legislation and is considered non-recurring in nature, the Company has presented this incremental amount under "Exceptional Item".

for and on behalf of the Board of Directors of
Narayana Hrudayalaya Limited

Dr. Emmanuel Rupert
Managing Director & Group CEO

Place: Bengaluru
Date: 31 July 2026

DELOITTE HASKINS & SELLS LLP
CHARTERED ACCOUNTANTS
BENGALURU

Narayana Hrudayalaya Limited

Narayana Hrudayalaya Limited
Registered office : No. 258/A, Bommasandra Industrial Area, Anekal Taluk, Bengaluru 560099, Karnataka, India
Corporate Office : 2nd Floor, No. 261/A, Bommasandra Industrial Area, Hosur Road, Bengaluru 560099, Karnataka, India
CIN : L85110KA2000PLC027497, Website: www.narayanahealth.org, Email: investorrelations@narayanahealth.org

ADDITIONAL DISCLOSURES AS PER REGULATION 52(4) OF SEBI (LISTING OBLIGATIONS AND DISCLSOURE REQUIREMENTS) REGULATIONS, 2015

Sl. No.	Particulars	Quarter ended			Year Ended
		30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
		(Unaudited)	(Unaudited) Refer Note 5	(Unaudited)	(Audited)
1	Debt equity ratio	0.73	0.76	0.65	0.76
2	Debt service coverage ratio	3.63	5.08	2.25	3.31
3	Interest service coverage ratio	6.58	7.81	4.83	6.13
4	Current ratio	1.49	1.47	1.41	1.47
5	Long term debt to working capital ratio	3.35	3.96	3.35	3.96
6	Bad debts to accounts receivable ratio	-	-	*	*
7	Current liability ratio **	0.30	0.27	0.34	0.27
8	Total debt to total assets ratio	0.33	0.34	0.30	0.34
9	Debtors turnover ratio	3.08	3.23	3.50	13.84
10	Operating margin(%)	21.80%	21.71%	18.98%	21.12%
11	Net profit margin(%)	12.57%	19.36%	9.26%	12.66%
12	Inventory turnover ratio	6.12	5.96	5.32	21.82
13	Capital redemption reserve/Debenture redemption reserve	NA	NA	NA	NA
14	Net worth (₹ in million)	27,318.16	25,974.32	22,726.25	25,974.32
15	The Company has not issued any secured listed non-convertible debt securities				

*values are insignificant
** comparative numbers have been adjusted to align with the results for the quarter and year ended 31 March 2026 and quarter ended 30 June 2026.

Formulae for computation of ratios are as follows

S.no	Particulars	Formulae	
		Numerator	Denominator
1	Debt equity ratio	Debt consist borrowings and lease liabilities	Total equity
2	Debt service coverage ratio	Earnings for debt service=Earnings before interest and tax	Debt Service=Finance cost & lease payments+principal repayments (excluding prepayment and working capital loan)
3	Interest service coverage ratio	Profit before taxes+Finance cost	Finance cost
4	Current ratio	Total current assets	Total current liabilities
5	Long term debt to working capital ratio	Long term borrowings (including current maturities of long term borrowings)	Current assets (-) Current liabilities [Excluding current maturities of long term borrowings]
6	Bad debts to accounts receivable ratio	Bad debts	Average gross trade receivables
7	Current liability ratio **	Total current liabilities	Total liabilities (without equity)
8	Total debt to total assets ratio	Total borrowings	Total assets
9	Debtors turnover ratio	Revenue from operations	Average trade receivables
10	Operating margin(%)	Earnings before depreciation, finance cost, tax and exceptional items (-) Other income	Revenue from operations
11	Net profit margin(%)	Net profit after taxes	Revenue from operations
12	Inventory turnover ratio	Cost of goods sold= Purchase of medical consumables, drugs and surgical instruments+Changes in inventories medical consumables, drugs, surgical instruments and other consumables	Average inventory

DELOITTE HASKINS & SELLS LLP CHARTERED ACCOUNTANTS BENGALURU

Narayana Hrudayalaya Limited

Deloitte Haskins & Sells LLP

Chartered Accountants
Prestige Trade Tower, Level 19
46, Palace Road, High Grounds
Bengaluru – 560 001
Karnataka, India

Tel: +91 80 6188 6000
Fax: +91 80 6188 6011

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
NARAYANA HRUDAYALAYA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **NARAYANA HRUDAYALAYA LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and other comprehensive loss of its associate and joint venture (including its subsidiary) for the quarter ended June 30, 2026 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the interim financial information of the entities listed in Annexure I.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of seven subsidiaries included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of Rs. 324.25 million for the quarter ended June 30, 2026, total net loss after tax of Rs. 150.78 million for the quarter ended June 30, 2026, and other comprehensive loss of Rs. 0.89 million for the quarter ended June 30, 2026, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

   Our conclusion on the Statement is not modified in respect of this matter.

7. The consolidated unaudited financial results includes the unaudited financial information of two subsidiaries (including one step down subsidiary), whose financial information reflect total revenues of Rs. Nil for the quarter ended June 30, 2026, total net loss after tax of Rs. 0.02 million for the quarter ended June 30, 2206, and other comprehensive loss of Rs. Nil for the quarter ended June 30, 2026, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of loss after tax of Rs 18.76 million for the quarter ended June 30, 2026, and other comprehensive loss of Rs. Nil for the quarter ended June 30, 2026, as considered in the Statement, in respect of one associate, one joint venture and one subsidiary of joint venture whose financial information have not been reviewed by us. These financial information are unaudited and have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, one associate, one joint venture and one subsidiary of joint venture, is based solely on such unaudited financial information. In our opinion and according to the information and explanations given to us by the Board of Directors, these financial information are not material to the Group.

   Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

8. The actuarial valuation of liabilities on insurance policies in force, Claims Incurred but Not Reported (IBNR), Claims Incurred but Not Enough Reported (IBNER) and Premium Deficiency Reserve (PDR), recorded in the unaudited interim financial information of the Narayana Health Insurance Limited (NHIL) and Cayman Integrated Healthcare Limited (CIHL) for the quarter ended June 30, 2026 has been duly estimated and certified by the respective Company's Appointed Actuary (the "Appointed Actuary") and in their opinion, the assumptions for such valuation are in accordance with generally accepted actuarial principles, the requirements of the Insurance Act, 1938, Insurance Act (Amendment), 2015, and the Actuarial Practice Standards and Guidance Notes of the Institute of Actuaries of India in concurrence with the Insurance Regulatory and Development Authority of India and the Insurance laws of Cayman, as may be applicable. We have relied upon the certificate of the Appointed Actuary of CIHL and NHIL during our review of the valuation of liabilities in respect of insurance policies in force, IBNR, IBNER and PDR which are included in the unaudited consolidated financial results of the Group, its associate and joint venture (including its subsidiary).

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

SATHYA PRAMOD KOUSHIK
Digitally signed by SATHYA PRAMOD KOUSHIK
Date: 2026.07.31 18:13:52 +05'30'

Sathya P. Koushik
Partner
(Membership No. 206920)
UDIN: 26206920IICXRN7272

Place: Bengaluru
Date: July 31, 2026
SPK/SG/TG/AB/2026

Deloitte Haskins & Sells LLP

Annexure I - List of entities included in the Consolidated Financial Results:

Sl.No.	Entity	Relationship
1.	Narayana Hrudayalaya Limited (NHL)	Parent
2.	Narayana Hospitals Private Limited (NHPL)	Subsidiary
3.	Meridian Medical Research & Hospital Limited (MMRHL)	Subsidiary
4.	Narayana Vaishno Devi Specialty Hospitals Private Limited (NVDSHPL)	Subsidiary
5.	Narayana Hrudayalaya Surgical Hospital Private Limited (NHSHPL)	Subsidiary
6.	Health City Cayman Islands Limited (HCCI)	Subsidiary
7.	Narayana Health North America LLC (NHNA)	Subsidiary
8.	Medha AI Private Limited (MAIPL)	Subsidiary
9.	Samyat Healthcare Private Limited (SHPL)	Subsidiary
10.	NH Integrated Care Private Limited (NHIC)	Subsidiary
11.	Narayana Health Insurance Limited (NHIL)	Subsidiary
12.	Athma Healthtech Private Limited (AHPL)	Subsidiary
13.	Narayana Healthcare North Private Limited (NHNPL)	Subsidiary
14.	Narayana Holdings Private Limited (NHDPL)	Subsidiary of HCCI
15.	Cayman Integrated Healthcare Limited (CIHL)	Subsidiary of HCCI
16.	ENT in Cayman Islands Limited (EICL)	Subsidiary of HCCI
17.	Narayana Hrudayalaya UK Ltd (NH UK)	Subsidiary of HCCI
18.	Reya Health Inc (RHI)	Associate of HCCI
19.	Everhope Oncology Private Limited (EOPL)	Joint venture of HCCI
20.	Samvaya Oncology Private Limited (SOPL)	Subsidiary of EOPL
21.	NH Health Bangladesh Private Limited (NHHBPL)	Subsidiary of NHDPL
22.	Practice Plus Group Hospitals Limited (PPGHL)	Subsidiary of NH UK
23.	Practice Plus Group Property Limited (PPGPL)	Subsidiary of NH UK
24.	Shepton Mallet Health Partnership Limited (SMHPL)	Subsidiary of PPGHL

Narayana Hrudayalaya Limited
Registered office : No. 258/A, Bommasandra Industrial Area, Anekal Taluk, Bengaluru 560 099, Karnataka, India
Corporate office : 2nd Floor, No. 261/A, Bommasandra Industrial Area, Hosur Road, Bengaluru 560 099, Karnataka, India
CIN : L85110KA2000PLC027497, Website: www.narayanahealth.org, Email: investorrelations@narayanahealth.org

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026

(₹ in Million, except per share data)

Sl. No.	Particulars	Quarter ended			Year ended
		30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
		(Unaudited)	Refer note 3 (Unaudited)	(Unaudited)	(Audited)
	Continuing operations				
1.	**Income**				
	(a) Revenue from operations	26,836.34	25,938.06	15,072.69	78,960.35
	(b) Other income	354.76	292.29	237.92	1,002.19
	Total income	**27,191.10**	**26,230.35**	**15,310.61**	**79,962.54**
2.	**Expenses**				
	(a) Purchases of medical consumables, drugs, surgical instruments and other consumables	5,203.06	5,246.19	3,053.99	15,603.81
	(b) Changes in inventories of medical consumables, drugs, surgical instruments and other consumables - (Increase) / Decrease	(60.24)	(179.90)	4.11	(442.68)
	(c) Employee benefits expense	7,248.38	7,488.85	2,955.23	18,029.81
	(d) Professional fees to doctors	3,270.10	2,412.09	2,441.78	10,987.38
	(e) Other expenses	6,478.02	5,871.00	3,248.07	18,615.31
	Expenses before depreciation and amortisation, finance costs and exceptional items	**22,139.32**	**20,838.23**	**11,703.18**	**62,793.63**
3.	**Earnings before depreciation and amortisation, finance costs and exceptional items (1-2) (EBITDA)**	**5,051.78**	**5,392.12**	**3,607.43**	**17,168.91**
4.	Finance costs	868.01	912.85	451.63	2,437.41
5.	Depreciation and amortisation expense	1,560.81	1,537.72	843.02	4,478.02
6.	**Total Expenses (2+4+5)**	**24,568.14**	**23,288.80**	**12,997.83**	**69,709.06**
7.	**Profit before tax and exceptional items (1-6)**	**2,622.96**	**2,941.55**	**2,312.78**	**10,253.48**
8.	Exceptional item (Refer Note 8)	-	(0.18)	-	(509.54)
9.	**Profit before share of loss of equity accounted investees and income tax (7+8)**	**2,622.96**	**2,941.37**	**2,312.78**	**9,743.94**
10.	Share of loss of equity accounted investees	(19.07)	(19.97)	(4.41)	(55.79)
11.	**Profit before tax (9+10)**	**2,603.89**	**2,921.40**	**2,308.37**	**9,688.15**
12.	Tax expense				
	(a) Current tax				
	-Current period/year	557.03	760.94	341.65	1,766.04
	(b) Deferred tax charge/(credit)	(25.84)	(119.87)	6.21	(182.48)
	Total tax expenses	**531.19**	**641.07**	**347.86**	**1,583.56**
13.	**Net Profit for the period/ year from continuing operations (11-12)**	**2,072.70**	**2,280.33**	**1,960.51**	**8,104.59**
14.	**Discontinued Operations (Refer Note 6)**				
	Profit/ (loss) before tax from discontinued operations	-	28.87	7.25	25.17
	Tax expense of discontinued operations	-	(7.22)	(0.69)	(7.91)
	Loss on disposal of discontinued operations	-	(62.06)	-	(62.06)
	Profit/(loss) for the period/ year from discontinued operations after taxes	-	**(40.41)**	**6.56**	**(44.80)**
15.	**Other comprehensive income from continuing operations**				
	Items that will not be reclassified subsequently to profit or loss				
	(i) Re-measurement gains/ (losses) on defined benefit plans	(52.54)	24.46	(11.40)	9.44
	(ii) Income tax effect	11.79	(6.17)	2.13	(3.09)
	(iii) Equity instruments through other comprehensive income, net	(12.31)	(16.85)	20.53	(22.96)
	Items that will be reclassified subsequently to profit or loss				
	(i) Effective portion of gains/ (losses) in cash flow hedges	(79.63)	-	1.73	(6.90)
	(ii) Income tax effect	-	-	(0.44)	-
	(iii) Effective portion of gains/ (losses) of net investment hedge in a foreign operation	-	(7.76)	(0.29)	(7.76)
	(iv) Exchange differences in translating the financial statement of foreign operations	0.44	971.34	(7.68)	1,998.47
	Other comprehensive income/ (loss), net of taxes from continuing operations	**(132.25)**	**965.02**	**4.58**	**1,967.20**
16.	**Other comprehensive income from discontinued operations (Refer Note 6)**				
	Items that will not be reclassified subsequently to profit or loss				
	(i) Re-measurement gains/ (losses) on defined benefit plans	-	0.79	(0.02)	(0.18)
	(ii) Income tax effect	-	-	-	-
	Other comprehensive income/ (loss), net of taxes from discontinued operations	-	**0.79**	**(0.02)**	**(0.18)**
17.	**Total comprehensive income (13+14+15+16)**	**1,940.45**	**3,205.73**	**1,971.63**	**10,026.81**
18.	**Net Profit attributable to:**				
	Owners of the company	2,071.78	2,238.78	1,966.51	8,055.99
	Non-controlling interests	0.92	1.14	0.56	3.80
	Net Profit for the period/ year	**2,072.70**	**2,239.92**	**1,967.07**	**8,059.79**
19.	**Other comprehensive income/ (loss) attributable to:**				
	Owners of the company	(132.25)	965.80	4.54	1,966.99
	Non-controlling interests	-	0.01	0.02	0.03
	Other comprehensive income/ (loss) for the period/ year	**(132.25)**	**965.81**	**4.56**	**1,967.02**
20.	**Total comprehensive income attributable to:**				
	Owners of the company	1,939.53	3,204.58	1,971.05	10,022.98
	Non-controlling interests	0.92	1.15	0.58	3.83
	Total comprehensive income for the period/ year (18+19)	**1,940.45**	**3,205.73**	**1,971.63**	**10,026.81**
21.	Paid-up equity share capital (Face value of ₹ 10 each)	2,043.61	2,043.61	2,043.61	2,043.61
22.	Reserves (Other Equity)				43,328.97
23.	Earnings per share (for continuing operations)	not annualised	not annualised	not annualised	annualised
	(of ₹ 10 each)				
	(a) Basic	10.20	11.22	9.65	39.89
	(b) Diluted	10.20	11.22	9.65	39.89
	Earnings per share (for discontinued operations)	not annualised	not annualised	not annualised	annualised
	(of ₹ 10 each)				
	(a) Basic	-	(0.20)	0.03	(0.22)
	(b) Diluted	-	(0.20)	0.03	(0.22)
	Earnings per share (for continuing and discontinued operations)	not annualised	not annualised	not annualised	annualised
	(of ₹ 10 each)				
	(a) Basic	10.20	11.02	9.68	39.67
	(b) Diluted	10.20	11.02	9.68	39.67
	See accompanying notes to the consolidated financial results				

DELOITTE HASKINS & SELLS LLP
CHARTERED ACCOUNTANTS
BENGALURU

Narayana Hrudayalaya Limited

Narayana Hrudayalaya Limited

Registered office : No. 258/A, Bommasandra Industrial Area, Anekal Taluk, Bengaluru 560 099, Karnataka, India

Corporate office : 2nd Floor, No. 261/A, Bommasandra Industrial Area, Hosur Road, Bengaluru 560 099, Karnataka, India

CIN : L85110KA2000PLC027497, Website: www.narayanahealth.org, Email: investorrelations@narayanahealth.org

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026

Notes :

1 The Statement of unaudited consolidated financial results ('the Statement') for the quarter ended 30 June 2026 of Narayana Hrudayalaya Limited (the 'Parent' / 'Company'), its subsidiaries (together referred to as the 'Group') and its share of loss in associate/joint venture (including its subsidiary) has been reviewed by the Audit, Risk and Compliance Committee and approved by the Board of Directors of the company at their respective meetings held on 31 July 2026. The Statutory Auditors have expressed an unmodified review conclusion on the unaudited consolidated financial results for the quarter ended 30 June 2026.

The aforesaid results along with limited review report of the Statutory Auditors on the unaudited consolidated financial results for the quarter ended 30 June 2026, is being filed with the National Stock Exchange of India Limited ("NSE") and BSE Limited and is also available on the Company's website.

2 The Statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard ("IND AS") 34 'Interim financial reporting' prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

3 The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures in respect of the financial year ended 31 March 2026 and the published year to date figures for the nine month ended 31 December 2025 which were subjected to limited review by the statutory auditors.

4 **Segment Information**

The Group's operating segments are 'Medical and Healthcare Related Services' and Others (Insurance Segment) and the disclosure pertaining to segments as per Regulation 33(1)(e) read with clause (L) of Part A of Schedule IV of the SEBI Regulations has been given below.

a) Segment revenues and results. **(₹ in Million)**

Sl. No.	Particulars	Quarter ended			Year ended
		30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
		(Unaudited)	Refer note 3 (Unaudited)	(Unaudited)	(Audited)
1	**Segment Revenue**				
	a)Revenue from operations				
	Medical and healthcare related services [1]	25,403.49	25,019.74	15,070.62	76,886.87
	Others	1,563.56	1,336.74	458.58	3,856.50
	Less: Inter segment revenue	(130.71)	(109.77)	(97.15)	(405.65)
	Total revenue from operations (a)	**26,836.34**	**26,246.71**	**15,432.05**	**80,337.72**
	Unallocated other income [1 & 3](b)	354.76	294.25	239.34	1,007.02
	Total income (a)+(b)	**27,191.10**	**26,540.96**	**15,671.39**	**81,344.74**
2	**Segment Result**				
	Medical and healthcare related services [1]	3,741.75	4,168.64	2,768.37	12,386.22
	Others	(624.61)	(599.70)	(240.46)	(1,241.90)
		3,117.14	3,568.94	2,527.91	11,144.32
	Add: Unallocated other income [1 & 3]	354.76	294.25	239.34	1,007.02
	Less: Finance cost [1]	868.01	912.92	451.63	2,438.02
	Profit before taxes	**2,603.89**	**2,950.27**	**2,315.62**	**9,713.32**
3	**Segment Assets**				
	Medical and healthcare related services [2]	102,443.72	103,217.89	58,783.92	103,217.89
	Others	3,427.17	3,085.16	1,600.92	3,085.16
	Unallocated [3]	21,853.69	18,440.99	13,446.36	18,440.99
	Total	**127,724.58**	**124,744.04**	**73,831.20**	**124,744.04**
4	**Segment Liabilities**				
	Medical and healthcare related services [2]	25,672.35	25,351.66	14,002.42	25,351.66
	Others	1,620.00	1,387.21	477.46	1,387.21
	Unallocated [3]	53,096.56	52,609.95	21,097.34	52,609.95
	Total	**80,388.91**	**79,348.82**	**35,577.22**	**79,348.82**
5	**Capital Employed**				
	(Segment Assets-Segment liabilities)				
	Medical and healthcare related services [2]	76,771.37	77,866.23	44,781.50	77,866.23
	Others	1,807.17	1,697.95	1,123.46	1,697.95
	Unallocated [3]	(31,242.87)	(34,168.96)	(7,650.98)	(34,168.96)
	Total	**47,335.67**	**45,395.22**	**38,253.98**	**45,395.22**

[1] Includes continuing and discontinued operations

[2] Includes Assets classified as held for sale and liabilities directly associated with assets classified as held for sale.

[3] Interest on fixed deposits, gain from mutual funds are not allocated to individual segments as the underlying instruments are managed at the corporate level. Similarly investments, fixed deposits, current taxes, deferred taxes and certain financial assets and liabilities are not allocated to segments as they are managed at the corporate level.

DELOITTE HASKINS & SELLS LLP CHARTERED ACCOUNTANTS BENGALURU

Narayana Hrudayalaya Limited

Narayana Hrudayalaya Limited

Registered office : No. 258/A, Bommasandra Industrial Area, Anekal Taluk, Bengaluru 560 099, Karnataka, India
Corporate office : 2nd Floor, No. 261/A, Bommasandra Industrial Area, Hosur Road, Bengaluru 560 099, Karnataka, India
CIN : L85110KA2000PLC027497, Website: www.narayanahealth.org, Email: investorrelations@narayanahealth.org

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026

5 The Board of Directors of the Company at its meeting held on 29 November 2024 approved the Scheme of Arrangement for the Merger of Meridian Medical Research & Hospital Ltd. (MMRHL), the subsidiary ("Transferor Company") with the Company ("Transferee Company") and their respective Shareholders and Creditors under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ("the Scheme") with 1 April 2024 as the appointed date and have recommended 1 (One) equity share of the Company to the shareholders of MMRHL (other than the Company) for every 2 (Two) fully paid-up equity shares of MMRHL.

The Stock Exchanges, BSE and NSE, after reviewing the Scheme filed with them by the Company on 20 December 2024 under Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, had issued "No Observation Letter" on 23 June 2025 and 24 June 2025, respectively under the said Regulations and the Scheme was filed with the Hon'ble National Company Law Tribunal, Bengaluru Bench (NCLT) on 27 September 2025.

Pursuant to the Order dated 2 December 2025 issued by the Hon'ble NCLT, the meetings of the Creditors and the Shareholders of the Transferor Company and the Transferee Company were held on 19 January 2026 who have passed the Scheme with more than requisite majority. Post approval by the Creditors and the Shareholders, a Petition along with the voting results has been filed with the Hon'ble NCLT on 23 January 2026. Notices were dispatched to all the Regulatory authorities for seeking their 'No Objection' with respect to the merger of MMRHL with the Company. Upon receipt of No-Objection letters from the Regulatory Authorities and basis the hearings, the Final Order by the Hon'ble NCLT is expected to be received in due course. Further there is no impact on results for the quarter ended 30 June 2026.

6 Narayana Vaishno Devi Speciality Hospitals Private Limited (NVDSHPL), a wholly owned subsidiary of the Company was running and operating the Shri Mata Vaishno Devi Narayana Superspeciality Hospital at Kakryal near Katra in Jammu which caters to patients across more than 20 different specialties, with radiology, obstetrics & gynaecology, oncology, etc. upto the closing hours of 31 March 2026. Pursuant to the Business Transition Agreement dated 25 March 2026 and the Management Agreement dated 28 March 2025, the business undertaking of Shri Mata Vaishno Devi Narayana Superspeciality Hospital has been transferred on a going concern basis to Shri Mata Vaishno Devi Charitable Society (SMVDCS). Accordingly, with effect from 01 April 2026, the ownership, operations and control of the Hospital stand vested with SMVDCS, and NVDSHPL continues to provide management and consultancy support in terms of the applicable agreements. Consequent to the aforesaid management agreement, the Company has assessed the carrying value of assets and liabilities to be transferred with recoverable value and written down an amount of ₹ 62.06 million in previous year.

Consequent to the above, the operations of NVD are considered as Discontinued operations and the impact of the same is as given below:

(₹ in Million)

Sl. No.	Particulars	Quarter ended			Year ended
		30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
		Unaudited			Audited
1	**Income**				
	Revenue from operations	-	308.65	359.36	1,377.37
	Other income	-	1.96	1.42	4.83
	Total income	-	**310.61**	**360.78**	**1,382.20**
2	**EXPENSES**				
	Purchase of medical consumables, drugs and surgical instruments	-	107.73	136.25	487.94
	Changes in inventories of medical consumables, drugs and surgical instruments - (increase) / decrease	-	(21.89)	(2.94)	(17.00)
	Employee benefits expense	-	58.24	64.60	253.32
	Professional fees to doctors	-	75.67	73.44	299.83
	Other expenses	-	57.90	78.05	309.97
	Expenses before depreciation and amortisation, finance costs and exceptional items	-	**277.65**	**349.40**	**1,334.06**
3	**Earnings before depreciation and amortisation, finance costs and exceptional items (1-2) (EBITDA)**	-	**32.96**	**11.38**	**48.14**
4	Finance costs	-	0.07	-	0.61
5	Depreciation and amortisation expense	-	4.02	4.13	16.51
6	**Total expense (2+4+5)**	-	**281.74**	**353.53**	**1,351.18**
7	**Profit before tax and exceptional items (1-6)**	-	**28.87**	**7.25**	**31.02**
8	Exceptional item	-	-	-	(5.85)
9	**Profit before tax (7+8)**	-	**28.87**	**7.25**	**25.17**
10	**Tax expense:**				
	a) Current Tax				
	Current period/year	-	7.22	0.69	7.91
	b) Deferred tax charge / (credit)	-	-	-	-
	Total tax expense	-	**7.22**	**0.69**	**7.91**
11	**Profit from discontinued operations after taxes (9-10)**	-	**21.65**	**6.56**	**17.26**
12	**Other Comprehensive Income from discontinued operations**				
	Items that will not be reclassified subsequently to profit or loss				
	(i) Re-measurement gains/ (losses) on defined benefit plans		0.79	(0.02)	(0.18)
	(ii) Income tax effect	-	-	-	-
	Other Comprehensive Income/ (losses), net of taxes from discontinued operations	-	**0.79**	**(0.02)**	**(0.18)**
13	**Total comprehensive income (11+12)**	-	**22.44**	**6.54**	**17.08**

7 The Board of Directors of the Company at the meeting held on 12 December 2025 had approved the Scheme of Arrangement between NH Integrated Care Private Limited (NHIC) (Wholly Owned Subsidiary) ["Demerged Company "], Narayana Hrudayalaya Limited ("Resulting Company") and their respective shareholders and creditors to demerge the clinical services as defined in the scheme of NHIC into the Resulting Company, while continuing the Narayana Aarogyam Vertical within NHIC, on a going concern basis under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ('the Scheme') with 1 April 2025 as the Appointed Date.

The Scheme was filed with the NCLT, Bengaluru Bench on 17 December 2025. Pursuant to the Order dated 13 February 2026 issued by the Hon'ble NCLT, the meetings of the Creditors and the Shareholders of the Demerged Company and the Resulting Company were held on 2 April 2026 who have passed the Scheme with more than requisite majority. Post approval by the Creditors and the Shareholders, a Petition along with the voting results has been filed with the Hon'ble NCLT on 8 April 2026. There will be no issuance of shares as consideration, in view of the Demerged Company being a wholly-owned subsidiary of the Resulting Company. Notices were dispatched to all the Regulatory Authorities for seeking their 'No Objection' with respect to above-mentioned scheme of arrangement. Upon receipt of No-Objection letters from the Regulatory Authorities and basis the hearings, the Final Order by the Hon'ble NCLT is expected to be received in due course. Further, there is no impact on results for the quarter ended 30 June 2026.

8 On 21 November 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "Labour Codes"). These Labour Codes consolidate twenty-nine existing labour laws into a unified framework governing employee benefits during and post-employment. The Labour Codes amongst other things introduced changes including a uniform definition of wages and enhanced benefit to leave.

The Group had assessed the financial implications of these changes which had resulted in increase in gratuity liability and leave liability arising out of past service cost by ₹ 509.54 million in the year ended 31 March 2026. As the impact arises from the enactment of new legislation and is considered non-recurring in nature, the Group has presented this incremental amount under "Exceptional Item". For one of the subsidiary the resulting increase in gratuity liability and leave liability arising out of past service cost had been considered in the quarter ended 31 March 2026.

9 The consolidated financial result include results of :

Subsidiaries of Narayana Hrudayalaya Limited (NHL)
Narayana Hospitals Private Limited (NHPL)
Meridian Medical Research & Hospital Limited (MMRHL)
Narayana Vaishno Devi Specialty Hospitals Private Limited (NVDSHPL)
Narayana Hrudayalaya Surgical Hospital Private Limited (NHSHPL)
Health City Cayman Islands Limited (HCCI)
Narayana Health North America LLC (NHNA)
Medha AI Private Limited (MAIPL)
Samyat Healthcare Private Limited (SHPL)
NH Integrated Care Private Limited (NHIC)
Narayana Health Insurance Limited (NHIL)
Athma Healthtech Private Limited (AHPL)
Narayana Healthcare North Private Limited (NHNPL) w.e.f 16 January 2026

Subsidiary of Health City Cayman Islands Limited (HCCI)
Narayana Holdings Private Limited (NHDPL)
Cayman Integrated Healthcare Limited (CIHL)
ENT in Cayman Islands Limited (EICL)
Narayana Hrudayalaya UK Ltd (NH UK) w.e.f 8 October 2025

Associate of Health City Cayman Islands Limited (HCCI)
Reya Health Inc

Joint Venture of Health City Cayman Islands Limited (HCCI)
Everhope Oncology Private Limited (EOPL) w.e.f 25 April 2025

Subsidiary of Narayana Holdings Private Limited (NHDPL)
NH Health Bangladesh Private Limited (NHBPL)

Subsidiary of Everhope Oncology Private Limited (EOPL)
Samvaya Oncology Private Limited (SOPL) w.e.f 18 June 2025

Subsidiary of Narayana Hrudayalaya UK Ltd (NH UK)
Practice Plus Group Hospitals Limited (PPG) w.e.f 6 November 2025
Practice Plus Group Property Ltd w.e.f 11 March 2026

Subsidiary of Practice Plus Group Hospitals Limited (PPG)
Shepton Mallet Health Partnership Limited w.e.f 6 November 2025

for and on behalf of the Board of Directors of
Narayana Hrudayalaya Limited

Dr. Emmanuel Rupert
Managing Director & Group CEO

Place: Bengaluru
Date: 31 July 2026

DELOITTE HASKINS & SELLS LLP
CHARTERED ACCOUNTANTS
BENGALURU

Narayana Hrudayalaya Limited

Narayana Hrudayalaya Limited
Registered office : No. 258/A, Bommasandra Industrial Area, Anekal Taluk, Bengaluru 560099, Karnataka, India
Corporate Office : 2nd Floor, No. 261/A, Bommasandra Industrial Area, Hosur Road, Bengaluru 560099, Karnataka, India
CIN : L85110KA2000PLC027497, Website: www.narayanahealth.org, Email: investorrelations@narayanahealth.org

ADDITIONAL DISCLOSURES AS PER REGULATION 52(4) OF SEBI (LISTING OBLIGATIONS AND DISCLSOURE REQUIREMENTS) REGULATIONS, 2015

Sl. No.	Particulars	Quarter ended			Year ended
		30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
		(Unaudited)	Refer note 3 (Unaudited)	(Unaudited)	(Audited)
1	Debt equity ratio	1.24	1.29	0.58	1.29
2	Debt service coverage ratio	2.23	2.06	2.41	2.36
3	Interest service coverage ratio	4.00	4.20	6.11	4.97
4	Current ratio	2.15	2.15	2.03	2.15
5	Long term debt to working capital ratio	1.97	2.12	1.34	2.12
6	Bad debts to accounts receivable ratio	-	*	*	*
7	Current liability ratio**	0.24	0.23	0.36	0.23
8	Total debt to total assets ratio	0.38	0.39	0.27	0.39
9	Debtors turnover ratio	3.95	3.69	2.58	13.04
10	Operating margin(%)	17.50%	19.66%	22.36%	20.47%
11	Net profit margin(%)	7.72%	8.79%	13.01%	10.26%
12	Inventory turnover ratio	3.26	3.48	2.78	11.45
13	Capital redemption reserve/Debenture redemption reserve	NA	NA	NA	NA
14	Net worth (₹ in Million)	47,312.11	45,372.58	38,234.60	45,372.58
15	The Company has not issued any secured listed non-convertible debt securities				

* Values are insignificant
** comparative numbers have been adjusted to align with the results for the quarter and year ended 31 March 2026.
The above computations are derived from continuing operations only.

Formulae for computation of ratios are as follows

S.no	Particulars	Formulae	
		Numerator	
1	Debt Equity Ratio	Debt consist borrowings and lease liabilities	Total equity
2	Debt Service Coverage Ratio	Earnings for debt service=Earnings before interest and tax (EBIT)	Debt Service=Finance cost+lease payments+principle repayments (excluding prepayment and working capital loan)
3	Interest Service coverage Ratio	Profit before taxes+Finance cost	Finance cost
4	Current Ratio	Total current assets	Total current liabilities
5	Long term debt to working capital ratio	Long term borrowings (Including current maturities of long term borrowings)	Current assets (-) Current liabities [Excluding current maturities of long term borrowings]
6	Bad debts to Accounts receivable ratio	Bad debts	Average gross trade receivables
7	Current liability ratio	Total current liabilities	Total liabilities
8	Total debt to total assets ratio	Total borrowings	Total assets
9	Debtors Turnover ratio	Revenue from operations	Average trade receivables
10	Operating margin(%)	Earnings before depreciation,finance cost,tax and exceptional items (-) other Income	Revenue from operations
11	Net Profit margin(%)	Net profit after taxes	Revenue from operations
12	Inventory turnover ratio	Cost of goods sold= Purchase of medical consumables, drugs and surgical instruments+Changes in inventories medical consumables, drugs, surgical instruments and other consumables	Average inventory

DELOITTE HASKINS & SELLS LLP CHARTERED ACCOUNTANTS BENGALURU

Narayana Hrudayalaya Limited